1. Home
  2. BBDO vs NTRA Comparison

BBDO vs NTRA Comparison

Compare BBDO & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Bradesco Sa

BBDO

Banco Bradesco Sa

HOLD

Current Price

$2.86

Market Cap

28.5B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$226.66

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBDO
NTRA
Founded
1943
2003
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BBDO
NTRA
Price
$2.86
$226.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
15
Target Price
$2.55
$238.20
AVG Volume (30 Days)
46.8K
1.1M
Earning Date
02-06-2026
11-06-2025
Dividend Yield
5.37%
N/A
EPS Growth
47.11
N/A
EPS
0.38
N/A
Revenue
$16,507,289,161.00
$2,116,676,000.00
Revenue This Year
$78.18
$33.18
Revenue Next Year
$7.75
$16.81
P/E Ratio
$8.10
N/A
Revenue Growth
16.68
38.17
52 Week Low
$1.74
$125.38
52 Week High
$3.31
$246.90

Technical Indicators

Market Signals
Indicator
BBDO
NTRA
Relative Strength Index (RSI) 45.82 47.93
Support Level $2.82 $227.89
Resistance Level $2.96 $237.04
Average True Range (ATR) 0.08 4.83
MACD -0.00 -1.75
Stochastic Oscillator 35.70 32.17

Price Performance

Historical Comparison
BBDO
NTRA

About BBDO Banco Bradesco Sa

Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: